Teva Provides Update On Generic Ortho Tri-Cyclen Lo
Jerusalem, Israel, July 17, 2009 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that further to its press release dated July 7, 2009, the Company and Ortho McNeil Janssen have extended their agreement to cease shipments of generic versions of Ortho Tri-Cyclen® Lo, until the earlier of (a) the Court's ruling on the motion for preliminary injunction or (b) July 29.
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the world's leading generic pharmaceutical company. The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80 percent of Teva's sales are in North America and Europe.